Hiromichi Oshiro

Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer

Kei Kawaguchi, Kentaro Miyake, Qinghong Han et al. · Cancer Letters · 2018 · 86 citations

Medicine, Oncology, Pharmacology +6

Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model

Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake et al. · Anticancer Research · 2018 · 73 citations · Full text

Medicine, Oncology, Pharmacology +14

Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma

Takashi Higuchi, Hiromichi Oshiro, Kentaro Miyake et al. · Anticancer Research · 2019 · 50 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer

Kei Kawaguchi, Kentaro Miyake, Qinghong Han et al. · Cell Cycle · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model

Hiromichi Oshiro, Yasunori Tome, Tasuku Kiyuna et al. · Anticancer Research · 2019 · 44 citations · Full text

Medicine, Oncology, Pharmacology +17